Just grabbed some more at $2.15... couldn't help myself.  Remember this is the same price area where they previously had two private offerings.  It should hold around here unless of course there is negative news from tomorrow's meeting.  Most of the selling this week and last has been on relatively low volume compared to the drop it caused in price.  If news from the meeting is positive, I think we easily see $3+ again...

 

Quote:

Originally Posted by Fizz1030 

Here's a post I found on the Yahoo board (so please take with a grain of salt):

 

"I have been in contact with Frank Reynolds and he tells me the company would not have any comment until it receives the FDA's official decision after the meeting which should be within 30-60 days.
So no reason to hold our breath on this for a while.
Share price may stagnate or slide again for a few more weeks.

Bob"

 

According to this poster, Frank indicates that they expect an official decision on the trials soon after this meeting.  At 2.25 x 2.28, I may have to grab some more shares.  However, it could very well go lower if we don't get news for a while...

 

News out on the meeting... Looks like everything is moving along as expected, albeit a bit slowly.  The press release doesn't give many details but does reiterate the company still expects approval and to begin the human trials in 2012 pending final approval from the FDA via an "open dialogue" process.  I just hope the FDA will approve the filing this year without delay.

InVivo Therapeutics Expects to Commence Human Study after Meeting on IDE Filing for Biopolymer Scaffolding to Treat Spinal Cord Injuries

Press Release: InVivo Therapeutics Holdings Corp. – 2 hours 34 minutes ago

http://finance.yahoo.com/news/invivo-therapeutics-expects-commence-human-100000815.html

My only regret is not grabbing more shares yesterday at the discounted prices, oh well.  I'll save my dry powder for the next round of impatient investors...  It looks like part of this drop was due to Frank selling around 260-270k shares last week (filing came out yesterday).  Not a big deal in the big picture, he owns 14million shares, so cashing in a few here and there is to be expected.  It also creates nice buying opportunities for the rest of us .  Back up to $2.50 today already... not too shabby.

 

Quote:

Originally Posted by amohedas 

They couldn't really have been much more specific given all the BS one has to deal with when getting approval from the FDA.  Sounds like the meeting was basically to hammer out some of the details on the trial protocol itself not about whether or not the technology is even legitimate etc.  This is big IMO and I expect approval for the trial to move forward within the next few months (the FDA is excruciatingly slow).

 

Also I like the fact that NVIV is moving forward on the other products as well. Fundamentals remain intact.
 

 

Is anyone able to get a quote on NVIV this morning?  My Ameritrade is not showing any trading.  Is it halted?

I saw this interesting article on the BBC today.  It looks like some UK researchers are thinking along the same lines as InVivo, giving credit to Frank's theory about how to help the spinal cord tissue regenerate.  They have only just begun experimenting in rats though.  Looking forward to the pending human trials.

http://www.bbc.co.uk/news/health-17783160

Miniature honeycomb 'grows nerve'

The scaffold can channel clusters of nerves through its honeycomb of holes, eventually healing a severed nerve.

The findings of their study on mouse nerves are published in the journal Biofabrication.

Academics hope to one day treat spinal cord injuries with the scaffold.

When nerves are severed, such as in car accidents, it can result in a loss of feeling and movement.

Repairing this damage can be a challenge - but nerves outside of the brain and spinal cord can repair themselves, if only over short distances.

Tube links

One technique to improve this repair is to use tubes. Either end of the severed nerve is placed in a tube and the two ends of the nerve should grow and join in the middle.

Researchers at the University of Sheffield and Laser Zentrum Hannover, Germany, investigated using a honeycomb structure.

Dr Frederik Claeyssens, from the department of materials science and engineering at Sheffield, told the BBC: "That is much more like the structure of the nerve itself.

"The nerve has small regions of 'cable' that go through from one end to the other end, you have a whole bunch of little cables inside a larger cable, that's what we tried to reproduce with this type of scaffold."

The honeycomb is made from photopolymerizable polylactic acid, which biodegrades once the nerve has repaired.

The researchers showed nerve cells could grow on the scaffold and are now testing it in mice to see if it can fully repair the damage.

Dr Frederik Claeyssens said: "This technology could make a huge difference to patients suffering severe nerve damage."

Scaffold technology is used in a range of "regenerative medicines". Building a scaffold and then coating it with human cells has, for example, been used to give patients new windpipes and bladders.

Looks like they are working under the assumption that they already have a green light from the FDA on human trials

8:58a ET May 11, 2012 (Business Wire)

Quote:

Originally Posted by amohedas 

Very light volume moving the stock to the $2.45-$2.50 area.  On an FDA approval of the clinical trial this is going to fly above $3 and fast.  Not many shares for sale at these levels.

 

The consolidation is looking good.

There's definitely strong support between 2.15-2.20.  I'm pretty confident this area holds seeing as how they had two previous offerings right around 2.10/share.  Once volume picks up I bet this will move quickly from these levels.  I am considering going to the annual meeting next week on 5/30 since I am close by just to see if they have anything new to say on the trials.

Quote:

Originally Posted by Fizz1030 

 

There's definitely strong support between 2.15-2.20.  I'm pretty confident this area holds seeing as how they had two previous offerings right around 2.10/share.  Once volume picks up I bet this will move quickly from these levels.  I am considering going to the annual meeting next week on 5/30 since I am close by just to see if they have anything new to say on the trials.

Fizz,

I have never attended a shareholders meeting but am really excited about InVivo and was thinking of attending.  Have you ever been to one and would say if its worth the trip?

I am concerned with this.... Will people likely be turned away?

Admission of shareholders to the Annual Meeting will be on a first-come, first-served basis, and picture
identification will be required to enter the Annual Meeting. An individual arriving without picture identification
will not be admitted unless it can be verified that the individual is an InVivo shareholder. Use of cameras,
cellular phones, recording equipment and other electronic devices will not be permitted at the Annual Meeting.
We reserve the right to inspect any persons or items prior to their admission to the Annual Meeting.

Only shareholders of record as of the close of business on Wednesday, April 18, 2012 are entitled to notice
of, and to vote at, the Annual Meeting. All shareholders are cordially invited to attend the meeting.

How do they know I am a shareholder?

Quote:

Originally Posted by weitzwb24 

 

Fizz,

 

I have never attended a shareholders meeting but am really excited about InVivo and was thinking of attending.  Have you ever been to one and would say if its worth the trip?

 

I am concerned with this.... Will people likely be turned away?

 

Admission of shareholders to the Annual Meeting will be on a first-come, first-served basis, and picture
identification will be required to enter the Annual Meeting. An individual arriving without picture identification
will not be admitted unless it can be verified that the individual is an InVivo shareholder. Use of cameras,
cellular phones, recording equipment and other electronic devices will not be permitted at the Annual Meeting.
We reserve the right to inspect any persons or items prior to their admission to the Annual Meeting.

 

Only shareholders of record as of the close of business on Wednesday, April 18, 2012 are entitled to notice
of, and to vote at, the Annual Meeting. All shareholders are cordially invited to attend the meeting.

 

How do they know I am a shareholder?

Hey Weitzwb24,

I have also never actually attended a shareholder meeting before, but I would assume you would be admitted as long as you have a photo ID and you owned shares as of April 18th as they stated.  I assume they will have a list of all shareholders on record as of 4/18 and then just check your photo ID to that list.  I'm not sure how big the room is where they are holding the meeting, but I doubt they would need to turn people away unless attendance was unexpectedly large.  I'm not sure if there will be any update on the business though (other than what we already know through press releases) as the schedule released in the proxy filing only lists the issues to be voted on:

To the Shareholders of InVivo Therapeutics Holdings Corp.:

Notice is hereby given that the Annual Meeting of Shareholders (the “Annual Meeting”) of InVivo Therapeutics Holdings Corp., a Nevada corporation, will be held on Wednesday, May 30, 2012 at 10:00 a.m., local time, at our corporate offices located at One Broadway, 14th Floor, Cambridge, Massachusetts 02142, for the following purposes:

The Board of Directors has no knowledge of any other business to be transacted at the Annual Meeting.

I would attend not to gain any info, but more just to experience a shareholders meeting.  I have never owned such a large part of a company as InVivo and would be interested in learning some of the other sides of owning a stock.  I mean if you owned shares of GE you would likely never make it to the meeting. 

The drive is only about three hours for me; seems like it could be an interesting learning experience.

Quote:

Originally Posted by weitzwb24 

I would attend not to gain any info, but more just to experience a shareholders meeting.  I have never owned such a large part of a company as InVivo and would be interested in learning some of the other sides of owning a stock.  I mean if you owned shares of GE you would likely never make it to the meeting. 

 

The drive is only about three hours for me; seems like it could be an interesting learning experience.

Looks like they will also be broadcasting the meeting online:

http://finance.yahoo.com/news/invivo-therapeutics-announces-webcast-annual-202500821.html

Quote:

Originally Posted by Fizz1030 

 

Looks like they will also be broadcasting the meeting online:

 

http://finance.yahoo.com/news/invivo-therapeutics-announces-webcast-annual-202500821.html

I have decided to attend.  The only problem I now have is the webcast says 9am and the proxy statement says 10am.....

Quote:

Originally Posted by weitzwb24 

 

I have decided to attend.  The only problem I now have is the webcast says 9am and the proxy statement says 10am.....

Yeah I saw that, I would call the investor relations # on their website to clarify the time if you are going to attend.  I will probably end up watching online.

Out of curiousity, I was doing some reading on the SCI human trials Geron Corp. had been working on a couple years ago prior to ending their SCI studies.  I decided to play around a bit with the numbers to see what kind of valuation we might expect as InVivo moves further along with the FDA approval process...

On January 23, 2009, Geron Corp. got approval from the FDA to begin human clinical trials using stem cells to treat patients with Acute SCI.  That day and during the weeks preceding the announcement the share price went from $5 to a high of $8.50, representing an increase of almost $300 million in Geron's market value.  Of course Geron's SCI treatment approach was different from InVivo's, but if we assume that the market would place the same valuation on an FDA go-ahead for InVivo's SCI human trials, that would yield a jump in share price of $4.70 ($300 million / 64 million O/S) based on the value of these trials alone (the increase could also be more/less depending on what was "built-in" in Geron's share price prior to the FDA approval and what is currently "built-in" in InVivo's share price).  Who knows what kind of price appreciation we'll see with InVivo as we approach the human trials, but I thought this was an interesting comparison.